174 related articles for article (PubMed ID: 21047977)
1. Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma.
Somlo G; Spielberger R; Frankel P; Karanes C; Krishnan A; Parker P; Popplewell L; Sahebi F; Kogut N; Snyder D; Liu A; Schultheiss T; Forman S; Wong JY
Clin Cancer Res; 2011 Jan; 17(1):174-82. PubMed ID: 21047977
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation.
Ladbury C; Somlo G; Dagis A; Yang D; Armenian S; Song JY; Sahebi F; Spielberger R; Popplewell L; Parker P; Forman S; Snyder D; Rincon A; Liu A; Frankel P; Wong J
Transplant Cell Ther; 2022 Jul; 28(7):367.e1-367.e9. PubMed ID: 35534000
[TBL] [Abstract][Full Text] [Related]
3. Total marrow irradiation as part of autologous stem cell transplantation for Asian patients with multiple myeloma.
Lin SC; Hsieh PY; Shueng PW; Tien HJ; Wang LY; Hsieh CH
Biomed Res Int; 2013; 2013():321762. PubMed ID: 24089671
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg/m²) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple Myeloma.
Cailleteau A; Maingon P; Choquet S; Bourdais R; Antoni D; Lioure B; Hulin C; Batard S; Llagostera C; Guimas V; Touzeau C; Moreau P; Mahé MA; Supiot S
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):677-685. PubMed ID: 36174802
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m
Patel P; Oh AL; Koshy M; Sweiss K; Saraf SL; Quigley JG; Khan I; Mahmud N; Hacker E; Ozer H; Peace DJ; Weichselbaum RR; Aydogan B; Rondelli D
Leuk Lymphoma; 2018 Jul; 59(7):1666-1671. PubMed ID: 29065747
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
7. Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.
Jo JC; Kang BW; Sym SJ; Lee SS; Jang G; Kim S; Lee DH; Kim SW; Lee JS; Suh C
Invest New Drugs; 2011 Feb; 29(1):175-81. PubMed ID: 19823768
[TBL] [Abstract][Full Text] [Related]
8. Tandem autologous hematopoietic cell transplantation with sequential use of total marrow irradiation and high-dose melphalan in multiple myeloma.
Giebel S; Sobczyk-Kruszelnicka M; Blamek S; Saduś-Wojciechowska M; Najda J; Czerw T; Mendrek W; Woźniak G; Jochymek B; Radwan M; Leszczyński W; Dolla Ł; D'Amico A; Ślosarek K; Hołowiecki J; Miszczyk L
Bone Marrow Transplant; 2021 Jun; 56(6):1297-1304. PubMed ID: 33339899
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
[TBL] [Abstract][Full Text] [Related]
10. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
12. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation.
Wong JY; Liu A; Schultheiss T; Popplewell L; Stein A; Rosenthal J; Essensten M; Forman S; Somlo G
Biol Blood Marrow Transplant; 2006 Mar; 12(3):306-15. PubMed ID: 16503500
[TBL] [Abstract][Full Text] [Related]
13. Total marrow irradiation with helical tomotherapy for bone marrow transplantation of multiple myeloma: first experience in Asia.
Shueng PW; Lin SC; Chong NS; Lee HY; Tien HJ; Wu LJ; Chen CA; Lee JJ; Hsieh CH
Technol Cancer Res Treat; 2009 Feb; 8(1):29-38. PubMed ID: 19166240
[TBL] [Abstract][Full Text] [Related]
14. Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation.
Wong JY; Rosenthal J; Liu A; Schultheiss T; Forman S; Somlo G
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):273-9. PubMed ID: 18786784
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
[TBL] [Abstract][Full Text] [Related]
16. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
17. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.
Abdelkefi A; Ladeb S; Torjman L; Othman TB; Lakhal A; Romdhane NB; Omri HE; Elloumi M; Belaaj H; Jeddi R; Aissaouï L; Ksouri H; Hassen AB; Msadek F; Saad A; Hsaïri M; Boukef K; Amouri A; Louzir H; Dellagi K; Abdeladhim AB;
Blood; 2008 Feb; 111(4):1805-10. PubMed ID: 17875806
[TBL] [Abstract][Full Text] [Related]
18. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
[TBL] [Abstract][Full Text] [Related]
20. Induction therapy in multiple myeloma.
Harousseau JL
Hematology Am Soc Hematol Educ Program; 2008; ():306-12. PubMed ID: 19074101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
